Transtema - Potential in power

Redeye retains its positive view of Transtema following a Q2 report roughly matching our expectations. Despite the strong growth, several presumable temporary negative factors limited the y/y margin improvement. On the other hand, the outlook within power is encouraging.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/